News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Wyeth Japan Obtains Approval For Anti-AML Agent Mylotarg



10/19/2005 5:09:02 PM

Tokyo (JCN) - Wyeth Japan announced on July 25 that it has obtained approval for Mylotarg, a proprietary preparation of gemtuzumab ozogamicin, from the Ministry of Health, Labor and Welfare. Mylotarg is a calicheamicin-conjugated humanized anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). AML is the most frequent leukemia in adults.

Read at JCN Newswire


comments powered by Disqus
Wyeth K.K.
Wyeth
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES